TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12025735

Group type: EXPERIMENTAL
Intervention: Somatosensory CNV paradigm with paired electrical stimuli as warning stimulus (WS) and imperative stimulus (IS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional CNV paradigm with a click sound as WS and a red light flash as IS
Number of subjects: 20
Study: 10498115

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation at a dosage of 400 IU per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation at a dosage of 500 to 1,000 mg per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 0
Study: 7585298

Group type: EXPERIMENTAL
Intervention: Liquid supplement containing fat (30 to 36 g) and cholesterol (650 to 780 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Liquid supplement that was fat and cholesterol free
Number of subjects: 49
Study: 2293357

Group type: EXPERIMENTAL
Intervention: Dipyridamole (100 mg orally q.i.d. for 2 days preoperatively, 5 mg/kg body weight/24 h i.v. peroperatively and 100 mg orally q.i.d. for 1 year postoperatively)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 360
Study: 6263091

Group type: EXPERIMENTAL
Intervention: Lithium (300 mg three times daily for 18 days of every 21 day chemotherapy cycle)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no lithium)
Number of subjects: 45
Study: 31927548

Group type: EXPERIMENTAL
Intervention: Combination of serum cystatin C (sCysC) and urinary N-Acetyl-Beta-D-glucosaminidase (uNAG)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Composite of sCysC and uNAG added to predictive model
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Composite of sCysC and uNAG
Number of subjects: 605

Group type: COMPARATOR
Intervention: sCysC, uNAG, and uACR individually
Number of subjects: 605

Group type: COMPARATOR
Intervention: uNAG plus uACR or sCysC plus uACR
Number of subjects: 605
Study: 28597708

Group type: EXPERIMENTAL
Intervention: Aerobic training on cycle ergometer (AT-group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Resistance training of the lower extremities (RT-group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham training of upper extremities (ST-group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: All groups (AT-group, RT-group, ST-group)
Number of subjects: 48
Study: 27855643

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic anticoagulation (PA group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional anticoagulation (TA group)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pharmacoeconomic analysis
Number of subjects: 300
Study: 24917273

Group type: EXPERIMENTAL
Intervention: Methotrexate (25 mg weekly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (1 g twice daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mycophenolate mofetil
Number of subjects: 80
Study: 22555266

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) in NYHA functional class I/II
Number of subjects: 667

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) in NYHA functional class III/IV
Number of subjects: 667
Study: 20632264

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Minilaparoscopic cholecystectomy (MLC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both SILC and MLC
Number of subjects: 70
Study: 18846541

Group type: EXPERIMENTAL
Intervention: Amantadine (400 mg/day)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study: 15830236

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wakefulness condition
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Zolpidem and Triazolam
Number of subjects: 22
Study: 11840184

Group type: EXPERIMENTAL
Intervention: Tamarind (10 g daily for 18 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study: 10231256

Group type: EXPERIMENTAL
Intervention: Asthma resource centre intervention with nurse specialists educating practice nurses and patients.
Number of subjects: 1621

Group type: EXPERIMENTAL
Intervention: Asthma resource centre intervention.
Number of subjects: 1621
Study: 9101833

Group type: EXPERIMENTAL
Intervention: Sequential transarterial chemoembolization (TA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Liver resection
Number of subjects: 39
Study: 1852516

Group type: EXPERIMENTAL
Intervention: Oral albuterol (0.15 mg/kg/dose q8h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (D5/W)
Number of subjects: 30
Study: 6365701

Group type: EXPERIMENTAL
Intervention: Aspirin (1,300 mg every 12 h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diflunisal (1,000 mg initially, then 500 mg every 12 h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30951624

Group type: EXPERIMENTAL
Intervention: Prosthetic treatment of missing teeth
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Treatment of caries
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Treatment of oral mucosal diseases
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Professional periodontal treatment
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Improvement of oral hygiene
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Oncological treatment of pre-cancerous and cancerous lesions
Number of subjects: 387
Study: 28970213

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control (DESIR cohort)
Number of subjects: 336
Study: 27064606

Group type: EXPERIMENTAL
Intervention: PLST-based intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 65
Study: 25385320

Group type: EXPERIMENTAL
Intervention: Indigenously prepared DFDBA from Tata Memorial Hospital (TMH) Tissue Bank
Number of subjects: 16

Group type: COMPARATOR
Intervention: DFDBA from Pacific Coast Tissue Bank (DEMBONE)
Number of subjects: 16
Study: 22747420

Group type: EXPERIMENTAL
Intervention: efonidipine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: cilnidipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: amiodipine
Number of subjects: 14
Study: 20025832

Group type: EXPERIMENTAL
Intervention: Non-dieting group interventions (10-week duration)
Number of subjects: 119
Study: 19138914

Group type: EXPERIMENTAL
Intervention: Pediatric airway exchange catheter (PAEC) in Group M (MIAS position)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pediatric airway exchange catheter (PAEC) in Group S (sniffing position)
Number of subjects: 100
Study: 15790202

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (PPH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Milligan‐Morgan haemorrhoidectomy (MM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 12094707

Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Cernitin pollen extract
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Combination of tamsulosin hydrochloride and cernitin pollen extract
Number of subjects: 243
Study: 10604884

Group type: COMPARATOR
Intervention: stent-placebo
Number of subjects: 491

Group type: COMPARATOR
Intervention: balloon-abciximab
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: stent-abciximab
Number of subjects: 491
Study: 8862090

Group type: EXPERIMENTAL
Intervention: GM‐CSF at 125 micrograms/m2/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GM‐CSF at 250 micrograms/m2/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study: 1805808

Group type: EXPERIMENTAL
Intervention: RoC 15+ A+B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sun E45 lotion SPF 15
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sun E45 cream SPF 25
Number of subjects: 0
Study: 6132229

Group type: EXPERIMENTAL
Intervention: Lyophilised human diploid-cell-strain rabies vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laboratory tests
Number of subjects: 0
Study: 31047857

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (physical training, cognitive training, nutritional counseling, cardiovascular monitoring) for 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (cognitive training, physical activity counseling, nutritional counseling) with omega-3 supplement for 3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unsupervised computer-based cognitive training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28992918

Group type: EXPERIMENTAL
Intervention: wildlife protection frame
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: cat benefit frame
Number of subjects: 512

Group type: COMPARATOR
Intervention: neutral frame
Number of subjects: 512
Study: 26803476

Group type: EXPERIMENTAL
Intervention: Intravesical Chemohyperthermia (CHT) with Mitomycin C (MMC)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Bacillus Calmette-Guérin (BCG)
Number of subjects: 190
Study: 24719123

Group type: EXPERIMENTAL
Intervention: Spot drug-eluting stent (DES) implantation
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Full lesion coverage
Number of subjects: 1619
Study: 22266897

Group type: EXPERIMENTAL
Intervention: Bupivacaine extended-release (150, 300, 450, or 600 mg)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Bupivacaine HCl 150 mg with epinephrine
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Bupivacaine extended-release
Number of subjects: 138
Study: 19329467

Group type: EXPERIMENTAL
Intervention: ECG guidance (n=121)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Landmark guidance (n=128)
Number of subjects: 249
Study: 16816963

Group type: EXPERIMENTAL
Intervention: ICARE lens
Number of subjects: 40

Group type: COMPARATOR
Intervention: Verisyse lens
Number of subjects: 40
Study: 17326351

Group type: EXPERIMENTAL
Intervention: Epi-LASIK (Moria Epi-K)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 20
Study: 15020522

Group type: EXPERIMENTAL
Intervention: Off-pump coronary bypass surgery
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: On-pump coronary bypass surgery
Number of subjects: 281
Study: 10770311

Group type: EXPERIMENTAL
Intervention: Doxycycline targeting Wolbachia spp bacteria
Number of subjects: 0
Study: 9342068

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) 4 mg/kg daily for 3 weeks followed by fluconazole 400 mg daily for 7 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Amphotericin B 0.7 mg/kg daily for 3 weeks followed by fluconazole 400 mg daily for 7 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome)
Number of subjects: 28
Study: 8450449

Group type: EXPERIMENTAL
Intervention: Constant triazolam infusion (mean concentration 2.48 ng/ml for 9 h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Step-infusion treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study: 3620274

Group type: EXPERIMENTAL
Intervention: isoxicam (maximum = 200 mg day‐1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: piroxicam (maximum = 20 mg day‐1)
Number of subjects: 57
Study: 30692242

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop with diluted insulin (U20)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hybrid closed-loop with standard strength insulin (U100)
Number of subjects: 24
Study: 27386745

Group type: EXPERIMENTAL
Intervention: High-oleic peanuts (56-84 g/day) for 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Habitual diet without peanuts for 12 weeks
Number of subjects: 61
Study: 25499006

Group type: EXPERIMENTAL
Intervention: DCLHb (diasiirin cross-linked hemoglobin) as add-on therapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 98
Study: 23453111

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 300 μg daily subcutaneous injection for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 22164957

Group type: COMPARATOR
Intervention: Dietary CLA 0%
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Dietary CLA 1%
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Dietary CLA 2%
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Dietary CLA 4%
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Dietary CLA (0%, 1%, 2%, 4%)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Dietary CLA (1%, 2%)
Number of subjects: 384
Study: 19930850

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 16917926

Group type: EXPERIMENTAL
Intervention: Protein+Carbohydrate (PC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Isocaloric‐Carbohydrate (IC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study: 15319458

Group type: EXPERIMENTAL
Intervention: Fetal tracheal occlusion (TO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 20
Study: 11450358

Group type: EXPERIMENTAL
Intervention: Ultrasonography and biochemical analysis after 3 weeks of controlled abstinence
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ultrasonography and biochemical analysis
Number of subjects: 30
Study: 9743952

Group type: EXPERIMENTAL
Intervention: Intermediate dose methotrexate (0.5 g/m2) (MHD-MTX) without cranial radiotherapy (CRT) in low-risk patients
Number of subjects: 4000

Group type: COMPARATOR
Intervention: MHD-MTX without CRT in intermediate-risk patients
Number of subjects: 4000

Group type: COMPARATOR
Intervention: MHD-MTX with 12 Gy or 18 Gy of preventive CRT in intermediate-risk patients
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) with reduced CRT (12 Gy for IR, 18 Gy for MR, and 18 Gy for HR)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Less intensive preventive CRT (12 Gy for all medium and high-risk patients) in trial ALL-BFM 90
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Combination of CRT (12 Gy) and HD-MTX in T-cell ALL patients
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Intensive systemic and intrathecal chemotherapy without CRT in low-risk ALL patients
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: CNS-directed systemic and intrathecal chemotherapy combined with 12 Gy CRT in trial ALL-BFM 90
Number of subjects: 4000
Study: 8053591

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (0.6, 1.0, and 1.4 MAC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (1.0 MAC) during surgical incision
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen (0.3, 0.45, and 0.6 MAC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lower anesthetic concentrations (associated with response to verbal command)
Number of subjects: 50
Study: 3183370

Group type: EXPERIMENTAL
Intervention: xipamide 20 mg once a day
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 31530044

Group type: EXPERIMENTAL
Intervention: Health-Related Productivity Questionnaire (HRPQ)
Number of subjects: 1686

Group type: COMPARATOR
Intervention: EM-I trial
Number of subjects: 1686

Group type: COMPARATOR
Intervention: EM-II trial
Number of subjects: 1686
Study: 31009067

Group type: EXPERIMENTAL
Intervention: Granger Mediation Analysis (GMA) framework applied to fMRI data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing approaches
Number of subjects: 0
Study: 28662647

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 54
Study: 25125353

Group type: EXPERIMENTAL
Intervention: Post-discharge ECG Holter monitoring
Number of subjects: 133
Study: 23696221

Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg via Rotadisk/Diskhaler
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg via Rotacap/Rotahaler
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo via Rotacap/Rotahaler
Number of subjects: 18
Study: 22067185

Group type: EXPERIMENTAL
Intervention: Bupivacaine extended-release 300 mg
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 19339560

Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional polyethylene (men)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (men)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene (women)
Number of subjects: 100
Study: 17010497

Group type: EXPERIMENTAL
Intervention: Two additional refresher classes at intervals of 7 and 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: One additional refresher class after 12 months
Number of subjects: 0
Study: 15526703

Group type: EXPERIMENTAL
Intervention: Perioperative clinical rotation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other clinical rotations
Number of subjects: 0
Study: 11209120

Group type: EXPERIMENTAL
Intervention: CO(2) laser (Silktouch mode, 260 handpiece, fluence 15 J/cm(2), 10 mm(2))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Electrosurgical device (ESD, 125 V = setting 4, 5 mm handpiece)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CO(2) laser
Number of subjects: 9

Group type: COMPARATOR
Intervention: Electrosurgical device (ESD)
Number of subjects: 9
Study: 9307630

Group type: EXPERIMENTAL
Intervention: Diffractive lens (811E, Pharmacia; power add +4.0 D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Refractive lens (PA154N, Allergan; power add +3.5 D)
Number of subjects: 80
Study: 8350885

Group type: EXPERIMENTAL
Intervention: Vest CPR (60 inflations per minute)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Vest CPR
Number of subjects: 49

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 49
Study: 3087656

Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg orally per day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Beclomethasone 100 micrograms in each nostril twice daily
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral astemizole
Number of subjects: 74
Study: 29662293

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 607
Study: 28805934

Group type: EXPERIMENTAL
Intervention: Dermo-cosmetics in combination with topical acne treatment (adapalene 0.1% gel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dermo-cosmetic products
Number of subjects: 0
Study: 26205644

Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Coadministration of sevoflurane and propofol (group C)
Number of subjects: 105
Study: 24001251

Group type: EXPERIMENTAL
Intervention: Project MARS intervention (sexual-risk-reduction intervention including screening and treatment for chlamydia and gonorrhea)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Project MARS intervention (including viral STIs in the economic analysis)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Project MARS intervention (contingent valuation model)
Number of subjects: 206
Study: 20384961

Group type: EXPERIMENTAL
Intervention: Ribavirin concentration ≥2 mg/L at day 29
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Ribavirin concentration <2 mg/L at day 29
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 12-week treatment group with ribavirin concentration ≥2 mg/L
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 12-week treatment group with ribavirin concentration <2 mg/L
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 24-week treatment group with ribavirin concentration ≥2 mg/L
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 24-week treatment group with ribavirin concentration <2 mg/L
Number of subjects: 382
Study: 19055294

Group type: EXPERIMENTAL
Intervention: Nanometer acupoint mounting method at 4 Jiaji points and other acupoints (Shenshu, Shangliao, Ciliao, Yang-lingquan, Xuanzhong)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zinc oxide sticking tablets at the same acupoints
Number of subjects: 60
Study: 16836477

Group type: EXPERIMENTAL
Intervention: FRIENDS Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 12971122

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment for Depression (BATD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Supportive Treatment
Number of subjects: 0
Study: 11105976

Group type: EXPERIMENTAL
Intervention: Tables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graphs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual Search Model (VSM)
Number of subjects: 0
Study: 9362196

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 25
Study: 8217176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: 8 mg of ondansetron
Number of subjects: 30

Group type: COMPARATOR
Intervention: 16 mg of ondansetron
Number of subjects: 30